Company intelligence / Profile preview
RHEACELL
Heidelberg, Germanyrheacell.com ↗
- Ownership
- Private
- Employees
- ~80
- Development stage
- Other
01
Overview
RHEACELL has received national marketing authorization in Germany for AMESANAR® for treating refractory patients with non-healing venous ulcers. The company is conducting Phase III trials for EBESANAR® for Epidermolysis Bullosa, with FDA granting approval for the Phase III study, marking a significant clinical milestone toward potential global approval[2][5].
- Therapeutic areas
- Rare DiseasesEndocrinologyCardiovascularDermatology
- Modalities
- Stem cell therapyABCB5+ mesenchymal stromal cells (MSCs)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Boston Children's HospitalBrigham and Women's HospitalHarvard Medical School
Beyond the preview
Go deeper on RHEACELL.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RHEACELL.